Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.
Longeveron has raised $30.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Longeveron's investors include Janus Henderson Investors, TEDCO, Alzheimer's Association, Coastlands Capital, Logos Capital.
Longeveron is headquartered in Miami, United States.
Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.
Longeveron is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Longeveron — Funding & Investors." VCBacked, March 10, 2026, https://www.vcbacked.co/company/longeveron. Accessed September 30, 2026.
VCBacked. (2026). Longeveron — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/longeveron
{{cite web |title=Longeveron — Funding & Investors |url=https://www.vcbacked.co/company/longeveron |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated